Navigation Links
Ganeden Biotech® Moves Its State-Of-The-Art Lab To Its World Headquarters In Cleveland
Date:1/15/2013

Cleveland, OH (PRWEB) January 15, 2013

Ganeden Biotech®, a recognized world leader in the manufacturing and marketing of probiotics, announces that its state-of-the-art lab has been moved to its world headquarters in Mayfield Heights, OH.

The company relocated its multi-million dollar lab from Miami to its Cleveland headquarters so that partners and customers could take best advantage of resources in a single facility.

The company’s state-of-the-art research and development facility is one of the most advanced probiotic technological research laboratories in the world. Guided by Lead Scientist, Dr. Howard Cash, the R&D organization has capabilities ranging from strain selection and genetic identification to product development support and stability testing. By working in partnership with licensees, Ganeden’s research team works to ensure the most stable, efficacious probiotic products available.

“Ganeden's lab facility enables us to serve as an R&D resource for our partners and clients. Through the use of our lab, our clients are able to bring top quality, well-researched products to market in a very short period of time,” said Mike Bush, Vice President, Business Development. “We are able to provide services ranging from formulation assistance, enumeration, stress testing, genetic sequencing and process refinement - all at no cost to our partners and clients.”

Ganeden’s 4,000 square-foot facility features an array of state of the art equipment including the 3130 Genetic Analyzer from Applied Biosystems and the 2100 Bioanalyzer from Agilent Technologies, which allow for verification of each lot of GanedenBC30 by PCR and genetic sequencing.

“In addition to the standard freezers, refrigerators, sterilizers, freeze dryers, incubators and bio-safety hoods typically found in a modern microbiology lab, we also have a full kitchen area used for preparing our customer’s products as a final consumer would do, before we test for viability of GanedenBC30,” Dr. Cash said.

GanedenBC30 can currently be found in more than 60 foods and beverage products including: baked goods, refrigerated beverages, drink mixes, prepared foods, milk and yogurt, confectionary products, nutrition bars and meal replacement powders.

“When we decided to invest in a lab expansion 7 years ago, we decided to invest in only the very best technologies so that our partners and clients would have access to state of the art resources. We are happy that they can now access this, along with all of Ganeden’s other resources, in a single location,” Bush said.

About Ganeden Biotech

Founded in 1997, Cleveland, Ohio based Ganeden Biotech is at the forefront of probiotic research and product development. Ganeden has an extensive library of published studies and more than 100 issued patents for probiotic technologies for the food, beverage, animal health, and now topical ingredients markets. The company is best known for GanedenBC30, its patented, probiotic ingredient, which is found in more than 60 leading food and beverage products. Ganeden helps manufacturers develop and market probiotic products and offers an extensive intellectual property portfolio with patent and trademark protection for an array of technologies all over the world.
For more information about Ganeden Biotech and licensing opportunities, visit ganedenbiotech.com.

Read the full story at http://www.prweb.com/releases/2013/1/prweb10322412.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Probiotic-Enriched Instant Chai Latte and Teas to be Launched by Ganeden Biotech and Tipton Mills
2. Ganeden Biotech Hires New Marketing Manager
3. Cord Blood America Announces DTCC Removes "Chill" Imposed in December 2010
4. Tiny levers, big moves in piezoelectric sensors
5. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
6. Graphene electronics moves into a third dimension
7. New imaging technique moves from lab to clinic
8. Instrumentation Laboratory Moves To Direct Distribution Of Hemostasis Product Line In North America
9. Antelope Valley Hospital Converts to Masimo rainbow SET for State-of-the-Art Noninvasive Patient Monitoring Capabilities
10. State-of-the-Art Novelda NVA6000 Impulse Radar Transceiver Finds Widespread Appeal and Applications
11. Healthpoint Biotherapeutics To Create State-of-the-Art Cell Sciences Manufacturing Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... and RESEARCH TRIANGLE PARK, N.C. ... (NASDAQ: UTHR ) announced today that ... of United Therapeutics will provide an overview and update ... st Annual Health Care Conference. The ... at 10:00 a.m. Eastern Time, and can be accessed ...
(Date:4/27/2016)... ... April 27, 2016 , ... PathSensors, Inc., ... Advisory Board. Dr. Lamka will assist PathSensors in expanding the use of the ... deploys the CANARY® test platform for the detection of harmful pathogens, including a ...
(Date:4/27/2016)... ... April 27, 2016 , ... Global Stem Cells Group and ... Symposium as other research and development initiatives for potential stem cell protocol management for ... Stem Cells Group executives began meeting to establish a working agenda and foster initiatives ...
(Date:4/26/2016)... ... April 27, 2016 , ... Cameron ... LLP as an associate in the firm’s Intellectual Property practice group. , Clients ... electromechanical patent applications. He has an electrical engineering and computer engineering background, and ...
Breaking Biology Technology:
(Date:3/9/2016)... 9, 2016 This BCC Research report provides ... the RNA Sequencing (RNA Seq) market for the years ... tools and reagents, data analysis, and services. ... the RNA-Sequencing market such as RNA-Sequencing tools and reagents, ... factors affecting each segment and forecast their market growth, ...
(Date:3/8/2016)... , March 8, 2016   Valencell ... technology, today announced it has secured $11M in ... GII Tech, a new venture fund being launched ... additional participation from existing investors TDF Ventures and ... funds to continue its triple-digit growth and accelerate ...
(Date:3/3/2016)... and DE SOTO, Kansas , March ... Detection Plus® to offer Oncimmune,s Early CDT®-Lung, a ... early detection of lung cancer Early CDT®-Lung ... and individuals. --> Early CDT®-Lung test to ... --> Oncimmune, a leader in early cancer ...
Breaking Biology News(10 mins):